Zonisamide for Weight Reduction in Obese Adults.
Phase of Trial: Phase II
Latest Information Update: 16 Jan 2017
At a glance
- Drugs Zonisamide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- 14 Aug 2013 Results published in JAMA: the Journal of the American Medical Association.
- 12 Nov 2012 Primary endpoint 'Bodyweight-reduction' has been met for 400 mg/day dosage, according to results in the Archives of Internal Medicine.
- 12 Nov 2012 Results published in the Archives of Internal Medicine.